생체 내 독성시험 시장 규모, 점유율, 동향 및 성장 분석 보고서(2026-2034년)

The In Vivo Toxicology Market size is expected to reach USD 10.89 Billion in 2034 from USD 6.41 Billion (2025) growing at a CAGR of 6.07% during 2026-2034.

The global in vivo toxicology market is expanding due to the growing need to evaluate the safety and toxicity of pharmaceutical compounds, chemicals, and medical products. In vivo toxicology studies involve testing substances in living organisms to assess potential health risks before clinical trials or commercial use. These studies are essential in drug development and regulatory approval processes.

Pharmaceutical and biotechnology companies are investing heavily in toxicology testing to ensure the safety of new drugs and therapeutic products. Increasing research activities and strict regulatory requirements for safety evaluation are driving demand for in vivo toxicology studies. Contract research organizations are also playing a key role by providing specialized toxicology testing services.

In the future, the market is expected to grow as drug development pipelines expand globally. The integration of advanced technologies and improved testing methodologies will enhance the efficiency of toxicology studies. While alternative testing approaches are emerging, in vivo toxicology will remain an important component of preclinical research and safety evaluation.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Product

• Instruments
• Consumables (Reagents & Kits, Animal Models)

By Test Type

• Acute
• Sub-Acute
• Sub-Chronic
• Chronic Test Type

By Testing Facility

• Outsourced Testing Facility
• In-House Testing Facility

By Toxicity End Point

• Immunotoxicity
• Systemic Toxicity
• Carcinogenicity
• Genotoxicity
• Development And Reproductive Toxicity
• Other Toxicity End Point

By End User

• Academic And Research Institutes
• Pharmaceutical & Biotechnology Companies
• Contract Research Organizations
• Others

COMPANIES PROFILED

• Charles River Laboratories, The Jackson Laboratory, Envigo, Taconic Biosciences Inc, genOway, Thermo Fisher Scientific, Danaher Corporation, Waters Corporation, Agilent Technologies, Shimadzu Corporation, Bruker Corporation
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL IN VIVO TOXICOLOGY MARKET: BY PRODUCT 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Product
• 4.2. Instruments Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Consumables (Reagents & Kits, Animal Models) Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL IN VIVO TOXICOLOGY MARKET: BY TEST TYPE 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Test Type
• 5.2. Acute Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Sub-Acute Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Sub-Chronic Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.5. Chronic Test Type Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL IN VIVO TOXICOLOGY MARKET: BY TESTING FACILITY 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Testing Facility
• 6.2. Outsourced Testing Facility Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. In-House Testing Facility Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL IN VIVO TOXICOLOGY MARKET: BY TOXICITY END POINT 2022-2034 (USD MN)

• 7.1. Market Analysis, Insights and Forecast Toxicity End Point
• 7.2. Immunotoxicity Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.3. Systemic Toxicity Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.4. Carcinogenicity Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.5. Genotoxicity Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.6. Development And Reproductive Toxicity Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.7. Other Toxicity End Point Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 8. GLOBAL IN VIVO TOXICOLOGY MARKET: BY END USER 2022-2034 (USD MN)

• 8.1. Market Analysis, Insights and Forecast End User
• 8.2. Academic And Research Institutes Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 8.3. Pharmaceutical & Biotechnology Companies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 8.4. Contract Research Organizations Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 8.5. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 9. GLOBAL IN VIVO TOXICOLOGY MARKET: BY REGION 2022-2034(USD MN)

• 9.1. Regional Outlook
• 9.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 9.2.1 By Product
  • 9.2.2 By Test Type
  • 9.2.3 By Testing Facility
  • 9.2.4 By Toxicity End Point
  • 9.2.5 By End User
  • 9.2.6 United States
  • 9.2.7 Canada
  • 9.2.8 Mexico
• 9.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 9.3.1 By Product
  • 9.3.2 By Test Type
  • 9.3.3 By Testing Facility
  • 9.3.4 By Toxicity End Point
  • 9.3.5 By End User
  • 9.3.6 United Kingdom
  • 9.3.7 France
  • 9.3.8 Germany
  • 9.3.9 Italy
  • 9.3.10 Russia
  • 9.3.11 Rest Of Europe
• 9.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 9.4.1 By Product
  • 9.4.2 By Test Type
  • 9.4.3 By Testing Facility
  • 9.4.4 By Toxicity End Point
  • 9.4.5 By End User
  • 9.4.6 India
  • 9.4.7 Japan
  • 9.4.8 South Korea
  • 9.4.9 Australia
  • 9.4.10 South East Asia
  • 9.4.11 Rest Of Asia Pacific
• 9.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 9.5.1 By Product
  • 9.5.2 By Test Type
  • 9.5.3 By Testing Facility
  • 9.5.4 By Toxicity End Point
  • 9.5.5 By End User
  • 9.5.6 Brazil
  • 9.5.7 Argentina
  • 9.5.8 Peru
  • 9.5.9 Chile
  • 9.5.10 South East Asia
  • 9.5.11 Rest of Latin America
• 9.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 9.6.1 By Product
  • 9.6.2 By Test Type
  • 9.6.3 By Testing Facility
  • 9.6.4 By Toxicity End Point
  • 9.6.5 By End User
  • 9.6.6 Saudi Arabia
  • 9.6.7 UAE
  • 9.6.8 Israel
  • 9.6.9 South Africa
  • 9.6.10 Rest of the Middle East And Africa

Chapter 10. COMPETITIVE LANDSCAPE

• 10.1. Recent Developments
• 10.2. Company Categorization
• 10.3. Supply Chain & Channel Partners (based on availability)
• 10.4. Market Share & Positioning Analysis (based on availability)
• 10.5. Vendor Landscape (based on availability)
• 10.6. Strategy Mapping

Chapter 11. COMPANY PROFILES OF GLOBAL IN VIVO TOXICOLOGY INDUSTRY

• 11.1. Top Companies Market Share Analysis
• 11.2. Company Profiles
  • 11.2.1 Charles River Laboratories
  • 11.2.2 The Jackson Laboratory
  • 11.2.3 Envigo
  • 11.2.4 Taconic Biosciences Inc
  • 11.2.5 GenOway
  • 11.2.6 Thermo Fisher Scientific
  • 11.2.7 Danaher Corporation
  • 11.2.8 Waters Corporation
  • 11.2.9 Agilent Technologies
  • 11.2.10 Shimadzu Corporation
  • 11.2.11 Bruker Corporation